Background Analysis: US FDA Advisory Committee to Review Novo Nordisk’s Insulin Degludec and Liraglutide (Xultophy) for Type 2 Diabetes – MAY 24, 2016 (EMDAC)
The US FDA has scheduled an Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting for Tuesday, May 24, 2016. The Committee will discuss the safety and efficacy of new drug application (NDA) 208583 for insulin degludec and liraglutide injection (Xultophy), submitted by Novo Nordisk Inc. (Novo), for the proposed indication of adjunct to diet and exercise to improve glycemic control in the treatment of adults with type 2 diabetes mellitus.
See the SAC Tracker report